Nevertheless, additional studies and tools are required to further decipher CD103 structure and bidirectional signaling, and to determine whether this integrin also undergoes conformational changes within the tumor ecosystem in order to control the affinity to its ligand E-cadherin and to regulate its functional properties. The gene discussed is CDH1; the disease is neoplasm.